1. Home
  2. CLPS vs LIXT Comparison

CLPS vs LIXT Comparison

Compare CLPS & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CLPS Incorporation

CLPS

CLPS Incorporation

N/A

Current Price

$1.00

Market Cap

26.8M

Sector

Technology

ML Signal

N/A

Logo Lixte Biotechnology Holdings Inc.

LIXT

Lixte Biotechnology Holdings Inc.

HOLD

Current Price

$6.98

Market Cap

26.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CLPS
LIXT
Founded
2005
2005
Country
Hong Kong
United States
Employees
N/A
3
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
26.8M
26.5M
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
CLPS
LIXT
Price
$1.00
$6.98
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
27.4K
170.0K
Earning Date
03-06-2026
05-08-2026
Dividend Yield
14.76%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.80
$0.64
52 Week High
$1.88
$7.50

Technical Indicators

Market Signals
Indicator
CLPS
LIXT
Relative Strength Index (RSI) 61.17 65.47
Support Level $0.85 $3.82
Resistance Level $1.05 $7.50
Average True Range (ATR) 0.05 0.79
MACD 0.01 -0.01
Stochastic Oscillator 83.20 73.18

Price Performance

Historical Comparison
CLPS
LIXT

About CLPS CLPS Incorporation

CLPS Inc. is an IT consulting and solutions provider serving international clients in the banking, wealth management, e-commerce, and automotive sectors. The company drives digital transformation using AI, cloud computing, and big data, offering IT consulting, customized solutions, virtual banking training, recruitment, professional training, and software services. It operates mainly in two segments: IT services, which generate the majority of its revenue, and academic education services. The company has a presence in Hong Kong, Singapore, Mainland China, India, Malaysia, and Japan, with the majority of its revenue coming from Mainland China.

About LIXT Lixte Biotechnology Holdings Inc.

Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.

Share on Social Networks: